329 related articles for article (PubMed ID: 21747388)
1. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.
Benson JM; Sachs CW; Treacy G; Zhou H; Pendley CE; Brodmerkel CM; Shankar G; Mascelli MA
Nat Biotechnol; 2011 Jul; 29(7):615-24. PubMed ID: 21747388
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
4. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
Benson JM; Peritt D; Scallon BJ; Heavner GA; Shealy DJ; Giles-Komar JM; Mascelli MA
MAbs; 2011; 3(6):535-45. PubMed ID: 22123062
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Deepak P; Loftus EV
Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
[TBL] [Abstract][Full Text] [Related]
7. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
8. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab: moving the target from psoriasis to Crohn's disease.
Settesoldi A; Coppola M; Rogai F; Annese V
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):5-13. PubMed ID: 24410468
[TBL] [Abstract][Full Text] [Related]
10. Update on ustekinumab for the treatment of Crohn's disease.
Leung Y; Panaccione R
Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
[TBL] [Abstract][Full Text] [Related]
11. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M; Alwawi E; Gordon KB
Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.
Aggeletopoulou I; Assimakopoulos SF; Konstantakis C; Triantos C
World J Gastroenterol; 2018 Sep; 24(36):4093-4103. PubMed ID: 30271076
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab.
Luo J; Wu SJ; Lacy ER; Orlovsky Y; Baker A; Teplyakov A; Obmolova G; Heavner GA; Richter HT; Benson J
J Mol Biol; 2010 Oct; 402(5):797-812. PubMed ID: 20691190
[TBL] [Abstract][Full Text] [Related]
15. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2012 Aug; 1263():1-12. PubMed ID: 22823582
[TBL] [Abstract][Full Text] [Related]
16. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Toussirot E
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Sandborn WJ; Feagan BG; Fedorak RN; Scherl E; Fleisher MR; Katz S; Johanns J; Blank M; Rutgeerts P;
Gastroenterology; 2008 Oct; 135(4):1130-41. PubMed ID: 18706417
[TBL] [Abstract][Full Text] [Related]
20. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
